Investors never know what to expect for Synovus
What analysts say:
- Buy, sell, or hold?: Analysts think investors should stand pat on Synovus with 14 of 21 analysts rating it hold. Analysts don't like Synovus as much as competitor First Horizon National overall. Ten out of 21 analysts rate First Horizon National a buy compared to five of 21 for Synovus. Analysts still rate the stock a hold, but they are a bit more wary about it compared to three months ago.
- Revenue forecasts: On average, analysts predict $299.9 million in revenue this quarter. That would represent a decline of 8.3% from the year-ago quarter.
- Wall Street earnings expectations: The average analyst estimate is a loss of $0.03 per share. Estimates range from a loss of $0.07 to a loss of $0.01.
What our community says:
CAPS All-Stars are solidly behind the stock with 85.7% granting it an "outperform" rating. The community at large agrees with the All-Stars with 86.5% assigning it a rating of "outperform." Fools are bullish on Synovus and haven't been shy with their opinions lately, logging 183 posts in the past 30 days. Despite the majority sentiment in favor of Synovus, the stock has a middling CAPS rating of three out of five stars.
Revenue has fallen for the past three quarters.
For all our Synovus-specific analysis, including earnings and beyond, add Synovus to My Watchlist.
Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.